by 
Market Overview:
Calcineurin inhibitors are a class of immunosuppressant drugs that are primarily used post-organ transplant to prevent rejection of the transplanted organ by the recipient’s immune system. The two most commonly used calcineurin inhibitors are cyclosporine and tacrolimus. They work by inhibiting calcineurin, a calcium-dependent phosphatase enzyme required for the immune system T-cell response. Calcineurin inhibitors have revolutionized transplant outcomes and significantly increased short and long-term survival rates for transplant recipients. They are considered the standard of care as primary immunosuppressants for the majority of solid organ transplants.
The global calcineurin inhibitor market is estimated to be valued at US$ 10.07 Billion in 2023 and is expected to exhibit a CAGR of 10 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trend driving the calcineurin inhibitor market growth is the rising number of organ transplant procedures being performed worldwide each year. According to the Global Observatory on Donation and Transplantation, over 140,000 solid organ transplantations were carried out globally in 2020, up from under 125,000 in 2010. The increase in transplantation rates can be attributed to growing organ donation programs, development of new surgical techniques, and better patient selection criteria. The rising transplant volumes directly translate to higher demand for potent immunosuppressants like calcineurin inhibitors. Another major trend is the development of new combination therapies and formulations of calcineurin inhibitors to improve efficacy, safety, and treatment compliance among patients.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in calcineurin inhibitor market is low as it requires high capital investment for R&D and commercialization of products. The market is dominated by major global players.
Bargaining power of buyers: The bargaining power of buyers is moderate due to availability of established brand products from major players. Generic alternatives provide choice to buyers.
Bargaining power of suppliers: The bargaining power of suppliers is low due to availability of substitutes and dominance of large players in supply chain.
Threat of new substitutes: The threat of new substitutes is moderate as research is ongoing for development of novel molecules and therapies.
Competitive rivalry: High as major players compete on basis of product differentiation, new product launches and market consolidation activities.
Key Takeaways
The global calcineurin inhibitor market is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing prevalence of autoimmune diseases, organ transplantation and rising healthcare expenditure.
Regional analysis: North America dominates the global market and holds majority market share owing to developed healthcare infrastructure, presence of key players and high adoption rate of newer therapies. Asia Pacific exhibits fastest growth rate due to improving access to healthcare facilities, rising awareness about diseases and increasing healthcare expenditure.
Key players operating in the calcineurin inhibitor market are Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Pfizer Inc., Incyte Corporation, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Sanofi SA, Bristol Myers Squibb Company, Mylan N.V., Dr. Reddy’s Laboratories Ltd., Senju Pharmaceutical Co. Ltd, Abbott, Lupin Limited, and Vibcare Pharma Pvt. Ltd. Key players are focused on new product launches, mergers and acquisitions for business expansion in emerging markets.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
